You searched for "retinal"

3573 results found

Fingolimod: ocular adverse effects

In this article the authors review the ocular side-effects of Fingolimod which is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). Fingolimod-associated macular oedema (FAME) is the most common ocular side-effect linked to this drug....

Clinical presentation, management, and outcomes in posterior segment open globe injuries

This is a retrospective, non-comparative, interventional case study of patients presenting with scleral and corneoscleral wounds covering a five-year period. It reports the clinical presentation, management, and factors affecting the outcomes of posterior segment open globe injuries (OGI) in 2360...

UK Eye Genetics Group (UK-EGG) 2024

by Mohammed Aslam, FY 3 Doctor, Calderdale and Huddersfield NHS Foundation Trust, UK. Founded in 2002, the UK EGG provides a hub to share knowledge on inherited eye disease and train the next generation of clinicians and scientists. This year’s...

ICG TTT for retinoblastoma

Transpupillary thermotherapy (TTT) is a specific form of ocular TT using infrared radiation (diode laser). Indocyanine green (ICG) is also used to achieve the optimal phototherapy effect in eyes with minimal pigment. Twenty-one patients with 42 retinoblastomas in 30 eyes...

Mainline Instruments Announces NHS Approval for iCare DRSplus Fundus Imaging System

Mainline Instruments is excited to share that the iCare DRSPlus Confocal Fundus Imaging System has received official approval from the NHS for use in the Diabetic Eye Screening (DES) Programme. This recognition follows a rigorous evaluation process, confirming that the...

ABDO welcomes two new regional leads for the North of England

The Association of British Dispensing Opticians (ABDO) is welcoming two new regional leads for the North of England. Lynda Matthias FBDO has been a dispensing optician for 20 years and works as a locum dispensing across Yorkshire. Over the past...

Pioneering eye device restores reading vision to blind eyes

A pivotal European clinical trial of a new electronic eye implant has seen remarkable results. The study, published in the New England Journal of Medicine, showed 84% of participants were able to read letters, numbers and words using prosthetic vision...

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...

Results of fixed aflibercept treatment regime in type 3 neovascularisation

In this prospective study the authors evaluate the effect of intravitreal aflibercept injections in the treatment of naive type 3 neovascularisation using a fixed treatment regime. Fourteen eyes of 14 patients were studied. All patients were treated with intravitreal 2.0...

The evolution and visual prognosis of glial proliferation of different grades after macular hole surgery

This retrospective research study aimed to investigate the evolution of glial proliferation of varying grades after successful idiopathic macular hole repair and its effects on foveal microstructure and best-corrected visual acuity (BCVA). Two-hundred and two eyes were enrolled in this...

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...

Aflibercept for the treatment of neovascular glaucoma

The aim of this study was to investigate initial results regarding the treatment of neovascular glaucoma (NVG) with intravitreal aflibercept. NVG is classified into stages 0-3. In stages 1 and 2, abnormal vessel proliferation is seen with or without elevated...